{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T05:14:54Z","timestamp":1648962894514},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00120-017-0517-y","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T07:38:32Z","timestamp":1507189112000},"page":"1424-1429","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patienten mit metastasiertem Prostatakarzinom"],"prefix":"10.1007","volume":"56","author":[{"given":"C.-H.","family":"Ohlmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"517_CR1","volume-title":"Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms","author":"Deutsche Krebsgesellschaft","year":"2016","unstructured":"Deutsche Krebsgesellschaft, Deutsche Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (2016) Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V., Berlin"},{"issue":"2","key":"517_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467\u2013479. \n                        https:\/\/doi.org\/10.1016\/j.eururo.2013.11.002","journal-title":"Eur. Urol."},{"issue":"2","key":"517_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(2):352\u2013360. \n                        https:\/\/doi.org\/10.1056\/NEJMoa1704174","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"517_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, De Bono JS, Spears MR et\u00a0al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338\u2013351. \n                        https:\/\/doi.org\/10.1056\/NEJMoa1702900","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"517_CR5","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00120-017-0464-7","volume":"56","author":"CH Ohlmann","year":"2017","unstructured":"Ohlmann CH, Miller K, Gschwend J (2017) Androgen deprivation plus abiraterone\/prednisone in metastatic hormone-sensitive prostate cancer : joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO). Urologe\u00a0A 56(9):1185\u20131186. \n                        https:\/\/doi.org\/10.1007\/s00120-017-0464-7","journal-title":"Urologe A"},{"issue":"1","key":"517_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.eururo.2011.08.026","volume":"61","author":"V Pagliarulo","year":"2012","unstructured":"Pagliarulo V, Bracarda S, Eisenberger MA et\u00a0al (2012) Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 61(1):11\u201325. \n                        https:\/\/doi.org\/10.1016\/j.eururo.2011.08.026","journal-title":"Eur. Urol."},{"issue":"14","key":"517_CR7","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL et\u00a0al (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368(14):1314\u20131325. \n                        https:\/\/doi.org\/10.1056\/NEJMoa1212299","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"517_CR8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","volume":"67","author":"ND James","year":"2015","unstructured":"James ND, Spears MR, Clarke NW et\u00a0al (2015) Survival with newly diagnosed metastatic prostate cancer in the \u201eDocetaxel era\u201c: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019). Eur Urol 67(6):1028\u20131038. \n                        https:\/\/doi.org\/10.1016\/j.eururo.2014.09.032","journal-title":"Eur. Urol."},{"issue":"2","key":"517_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a\u00a0randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149\u2013158. \n                        https:\/\/doi.org\/10.1016\/S1470-2045(12)70560-0","journal-title":"Lancet Oncol."},{"issue":"2","key":"517_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2015","unstructured":"Gravis G, Boher JM, Joly F et al (2015) Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol 70(2):256\u2013262. \n                        https:\/\/doi.org\/10.1016\/j.eururo.2015.11.005","journal-title":"Eur. Urol."},{"issue":"18_suppl","key":"517_CR11","doi-asserted-by":"publisher","first-page":"LBA2","DOI":"10.1200\/jco.2014.32.18_suppl.lba2","volume":"32","author":"C Sweeney","year":"2014","unstructured":"Sweeney C, Chen Y, Carducci MA et al (2014) Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrca): an ECOG-led phase III randomized trial. J\u00a0Clin Oncol 32(18_suppl):LBA2\u2013LBA2. \n                        https:\/\/doi.org\/10.1200\/jco.2014.32.18_suppl.lba2","journal-title":"J Clin Oncol"},{"issue":"8","key":"517_CR12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N\u00a0Engl J Med 373(8):737\u2013746. \n                        https:\/\/doi.org\/10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"issue":"2_suppl","key":"517_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1200\/jco.2016.34.2_suppl.162","volume":"33","author":"ND James","year":"2015","unstructured":"James ND, Sydes MR, Mason M et al (2015) Docetaxel and\/or zoledronic acid for hormone-na\u00efve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J\u00a0Clin Oncol 33(2_suppl):162\u2013162. \n                        https:\/\/doi.org\/10.1200\/jco.2016.34.2_suppl.162","journal-title":"J Clin Oncol"},{"issue":"36","key":"517_CR14","doi-asserted-by":"publisher","first-page":"5936","DOI":"10.1200\/JCO.2007.15.9830","volume":"26","author":"RE Millikan","year":"2008","unstructured":"Millikan RE, Wen S, Pagliaro LC et\u00a0al (2008) Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J\u00a0Clin Oncol 26(36):5936\u20135942. \n                        https:\/\/doi.org\/10.1200\/JCO.2007.15.9830","journal-title":"J Clin Oncol"},{"key":"517_CR15","volume-title":"Clinical trial design and chemotherapy use in prostate cancer: correcting old mistakes, making new ones. Discussant of abstr. 5001","author":"IF Tannock","year":"2015","unstructured":"Tannock IF, Amir E (2015) Clinical trial design and chemotherapy use in prostate cancer: correcting old mistakes, making new ones. Discussant of abstr. 5001. ASCO Annual Meeting 2015, Chicago, 29.05. - 02.06.2015."},{"issue":"4","key":"517_CR16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.eururo.2015.09.013","volume":"69","author":"M Tucci","year":"2016","unstructured":"Tucci M, Bertaglia V, Vignani F et al (2016) Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol 69(4):563\u2013573. \n                        https:\/\/doi.org\/10.1016\/j.eururo.2015.09.013","journal-title":"Eur. Urol."},{"issue":"2","key":"517_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale CL, Burdett S, Rydzewska LH et al (2016) Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a\u00a0systematic review and meta-analyses of aggregate data. Lancet Oncol 17(2):243\u2013256. \n                        https:\/\/doi.org\/10.1016\/S1470-2045(15)00489-1","journal-title":"Lancet Oncol."},{"issue":"8","key":"517_CR18","doi-asserted-by":"publisher","first-page":"335.e9","DOI":"10.1016\/j.urolonc.2016.03.003","volume":"34","author":"A Ramos-Esquivel","year":"2016","unstructured":"Ramos-Esquivel A, Fernandez C, Zeledon Z (2016) Androgen-deprivation therapy plus chemotherapy in metastatic hormone-sensitive prostate cancer. A systematic review and meta-analysis of randomized clinical trials. Urol Oncol 34(8):335.e9\u2013335.e1. \n                        https:\/\/doi.org\/10.1016\/j.urolonc.2016.03.003","journal-title":"Urol Oncol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-017-0517-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-017-0517-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-017-0517-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T09:42:21Z","timestamp":1509702141000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-017-0517-y"}},"subtitle":["Empfehlungen zur prim\u00e4ren Hormon- oder Hormonchemotherapie"],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1007\/s00120-017-0517-y","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}